Chris Emerson
Chris Emerson holds a doctorate in small molecule chemistry from Oregon State University (2011), with scientific training focused on molecular design, structure-activity relationships, and the pharmacological behavior of small molecules at biological targets. That foundation shapes how he approaches cannabinoid science: not as a category of wellness ingredients to be marketed, but as a class of pharmacologically active compounds whose interactions with human biology demand the same rigor applied to any serious drug discovery program.
In 2012, he developed the founding thesis behind what would become LEVEL: that effects-driven cannabinoid formulations, built from specific ratios of acidic cannabinoids, neutral cannabinoids, and nonenzymatic degradative byproducts, could deliver targeted, reproducible outcomes that the plant itself cannot provide. The insight was grounded in a simple observation that remained largely unaddressed by the industry. Most people who had tried cannabis, or who were hesitant to try it, described the same three experiences: tiredness, hunger, and paranoia. These were not inevitable pharmacological facts. They were the predictable result of an industry relying on uncontrolled, inconsistent phytochemical inputs and calling the outcome medicine.
Effects-driven formulation, built on consistency, reproducibility, transparency, and efficacy, was a tractable solution. Verifying it required science the industry had not yet fully understood nor implemented. LEVEL was built to do that science, and to do it more rigorously anyone else. The approach integrates engineering, software, and AI-assisted analysis to create products and processes that make rigorous observational research and real-world data collection possible on a meaningful scale.
LEVEL’s U.S. Patent No. 12,076,442 B1, granted September 2024, covers an activated cannabinoid controlled-release delivery system using mesoporous silica as a hosting compound, enabling oral cannabinoid formulations with known, stable, and reproducible potency at the tablet level. LEVEL conducted an IRB-approved, decentralized, randomized, triple-blind, and placebo-controlled clinical trial evaluating oral cannabigerol in U.S. military veterans with longstanding sleep challenges, published in Medical Cannabis and Cannabinoids (2026). The trial did not demonstrate statistically significant differences on primary sleep outcomes. That result is reported without revision because intellectual honesty about null results is precisely what distinguishes scientific work from the marketing claims this industry defaults to.
The positions taken in LEVEL’s canonical guides reflect Chris’s scientific assessment of current evidence. Where LEVEL’s research is referenced, it is cited specifically and with appropriate context. These documents are intended to function as industry references, not product endorsements. The goal is not to establish what cannabinoids claimed to do. It is to establish, as precisely as current evidence allows, what they actually do.
Conflict of Interest Disclosure
Chris Emerson is an employee, shareholder, and fiduciary officer of Metta Medical dba LEVEL. LEVEL produces and sells cannabinoid formulation products, including products containing acidic cannabinoids. This financial relationship is disclosed explicitly in every canonical guide produced under this authorship. The conflict of interest does not alter the scientific standard applied to evidence assessment, but readers should weigh it accordingly.
Selected Publications and Patents
Cannabinoid Science
Emerson CR, Webster CE, Daza EJ, Klamer BG, Tummalacherla M. Effect of Cannabigerol on Sleep and Quality of Life in Veterans: A Decentralized, Randomized, Placebo-Controlled Trial. Med Cannabis Cannabinoids. 2026;9(1):1-14. Published online December 9, 2025. doi: 10.1159/000549902
ClinicalTrials.gov Identifier: NCT05088018. IRB: Advarra. Protocol: VetsECS21.
Organic and Small Molecule Chemistry
Emerson CR, Zakharov LN, Blakemore PR. Investigation of Functionalized alpha-Chloroalkyllithiums for a Stereospecific Reagent-Controlled Homologation Approach to the Analgesic Alkaloid (-)-Epibatidine. Chem Eur J. 2013;19(48):16342-16356. doi: 10.1002/chem.201302511
Emerson CR, Zakharov LN, Blakemore PR. Iterative Stereospecific Reagent-Controlled Homologation Using a Functionalized alpha-Chloroalkyllithium: Synthesis of Cyclic Targets Related to Epibatidine. Org Lett. 2011;13(6):1318-1321. doi: 10.1021/ol103170y
Sephton MA, Emerson CR, Zakharov LN, Blakemore PR. Spontaneous Symmetry Breaking During Interrupted Crystallization of an Axially Chiral Amino Acid Derivative. Chem Commun. 2010;46:2094. doi: 10.1039/B922028C
Patents
Emerson CR, et al. Activated Cannabinoid Controlled Release Compound Tablet and Method of Forming the Same. U.S. Patent No. 12,076,442 B1. Granted September 3, 2024.
Emerson CR, et al. Activated Cannabinoid Controlled Release Compound Tablet and Method of Forming the Same. U.S. Patent No. 11,596,606 B2. Granted March 2023.
Education
PhD, Small Molecule Chemistry, Oregon State University, 2011. Blakemore Research Group. Dissertation focus: development of enantioenriched organometallic reagents via asymmetric halogen-metal exchange and deployment of functionalized scalemic carbenoids in stereospecific reagent-controlled homologation chemistry.
BS, Professional Chemistry, University of Nevada, Reno, 2005. Undergraduate research under Professor Suk-Wah Tam-Chang: design and synthesis of hetero-bifunctional linked compounds functioning as molecular probes for DNA chip and array applications.
This author page is a living document that is updated as new research is completed and published. Last updated: March 2026.
Posts
Our Expertise
Blog
Elevate Your Cannabis IQ.
CULTIVATED.NEWS Podcast Interviews Chris Emerson PhD
About LEVEL, Cannabinoids, ScienceThe Entourage Collection: A Cannabinoid for Every Occasion
by Janelle Lassalle
About LEVEL, Cannabinoids, ScienceExploring Natural Wellness Solutions with CBD, CBDa, and CBG
by Janelle Lassalle
Are You 21 or Older?
Sorry, you must be 21 or older to visit this site.